Midomafetamine

PharmAla Biotech contracted as GMP LaNeo™ MDMA supplier for Mt. Sinai Health System clinical trial. PharmAla and CCrest Labs terminated their supply agreement. PharmAla focuses on MDXX class molecules, including MDMA, for clinical trials and commercial sales.

Massachusetts may legalize certain plant-based psychedelics on Nov. 5, following Oregon and Colorado. The Natural Psychedelic Substances Act aims to regulate access to psilocybin, DMT, mescaline, and ibogaine at licensed therapy centers. Experts warn of safety and purity concerns, suggesting FDA approval of purified, synthetic molecules is the safest path. Despite potential implementation challenges, state initiatives and pharmaceutical development may coexist.

Ibogaine induces intense hallucinations, while tabernanthalog, a non-hallucinogenic analogue, offers altered states without trips. The definition of a trip is evolving as researchers develop non-hallucinogenic psychedelics for medical use, raising questions about what constitutes a psychedelic experience.

Saint Lucia launched an Early Warning System (EWS) to monitor drug-related threats, involving a network of experts and agencies. The EWS issues alerts for health-related trends linked to illegal drugs, as demonstrated by its success in other Caribbean islands. The system relies on information from various sectors and aims to improve public health and safety.

The Ministry of Health, Wellness, and Elderly Affairs, in collaboration with the OAS, launched an Early Warning System (EWS) in Saint Lucia to monitor and address emerging drug threats. The EWS, a multi-agency network, aims to facilitate rapid communication and enhance intervention strategies. Ching-Soto of the OAS emphasized the urgency of the initiative, highlighting Saint Lucia's role as a transit point for drug trafficking and the potential infiltration of synthetic drugs. The EWS launch marks a significant milestone in combating the growing drug issue, reflecting the commitment of Saint Lucia's government and stakeholders.

The article discusses psilocybin's classification, therapeutic potential, and varying state laws. It highlights the growing interest in psychedelics for treating conditions like depression and PTSD. The article also addresses the legality of microdosing psilocybin, noting its federal illegality but varying state and local enforcement priorities. It provides examples of cities in California that have made psilocybin use a low enforcement priority. The article concludes with recommendations for employers dealing with employees microdosing at work, emphasizing the importance of clear policies and a safe workplace.

Pharmaceutical companies are developing safer psychedelic drugs for psychotherapy, with MindMed creating R-MDMA with fewer side effects. Other companies aim to synthesize DMT for longer-lasting depression relief. Despite MDMA's Schedule I status, studies suggest it treats PTSD and depression. Countries like Portugal and Australia have decriminalized or legalized MDMA for personal use or therapy. Mindstate uses AI to understand brain effects and received FDA approval for human trials of MSD-001, targeting specific serotonin receptors.

A European study suggests 'magic' mushrooms, specifically psilocybin, are more effective at treating depression than conventional SSRIs, with rapid and lasting benefits. Psilocybin, granted 'breakthrough therapy' status by the FDA, may rewire the brain, offering relief to those with treatment-resistant depression. Challenges include stigma, cost, and the need for supervised administration.

At TD Cowen’s September 26th panel, 'Advancement in Psychedelic Therapies for Neuropsychiatry,' execs from atai Life Sciences, Cybin, and GH Research discussed Lykos’ new drug application, psychedelic trial design, and the broader field. atai CEO Srini Rao emphasized the FDA’s consistent standards for psychedelics, referencing Janssen’s Spravato approval. Cybin’s CSO, Amir Inamdar, criticized Lykos’ psychotherapeutic approach as unethical, and highlighted the impracticality of psychotherapy during active dosing sessions.

The article discusses psilocybin's therapeutic potential, state laws on its use, and employer responses to employee microdosing. It highlights federal illegality under the Controlled Substances Act, contrasting with state-level decriminalization efforts. Employers are advised to clarify drug use policies, offer employee assistance programs, and ensure safety in safety-sensitive roles.